vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与VICOR CORP（VICR）财务数据对比。点击上方公司名可切换其他公司
VICOR CORP的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.5倍（$113.0M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 20.2%），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 14.7%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
Vicor Corporation是总部位于美国马萨诸塞州安多弗的电源模块专业制造商，深耕高性能电源模块的研发、生产与销售，可为多个行业客户提供高效可靠的电源解决方案，在全球电源技术领域具备较强的技术优势与市场竞争力。
PBYI vs VICR — 直观对比
营收规模更大
VICR
是对方的1.5倍
$75.5M
营收增速更快
PBYI
高出7.5%
20.2%
两年增速更快
PBYI
近两年复合增速
14.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $113.0M |
| 净利润 | — | $20.7M |
| 毛利率 | 69.3% | — |
| 营业利润率 | 22.7% | 59.7% |
| 净利率 | — | 18.3% |
| 营收同比 | 27.7% | 20.2% |
| 净利润同比 | — | 713.9% |
| 每股收益（稀释后） | $0.26 | $0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYIVICR
| Q1 26 | — | $113.0M | ||
| Q4 25 | $75.5M | $107.3M | ||
| Q3 25 | $54.5M | $110.4M | ||
| Q2 25 | $52.4M | $96.0M | ||
| Q1 25 | $46.0M | $94.0M | ||
| Q4 24 | $59.1M | $96.2M | ||
| Q3 24 | $80.5M | $93.2M | ||
| Q2 24 | $47.1M | $85.9M |
净利润PBYIVICR
| Q1 26 | — | $20.7M | ||
| Q4 25 | — | $46.5M | ||
| Q3 25 | $8.8M | $28.3M | ||
| Q2 25 | $5.9M | $41.2M | ||
| Q1 25 | $3.0M | $2.5M | ||
| Q4 24 | — | $10.2M | ||
| Q3 24 | $20.3M | $11.6M | ||
| Q2 24 | $-4.5M | $-1.2M |
毛利率PBYIVICR
| Q1 26 | — | — | ||
| Q4 25 | 69.3% | 55.4% | ||
| Q3 25 | 77.7% | 57.5% | ||
| Q2 25 | 76.5% | 95.9% | ||
| Q1 25 | 77.1% | 47.2% | ||
| Q4 24 | 76.4% | 52.4% | ||
| Q3 24 | 63.9% | 49.1% | ||
| Q2 24 | 77.4% | 49.8% |
营业利润率PBYIVICR
| Q1 26 | — | 59.7% | ||
| Q4 25 | 22.7% | 14.6% | ||
| Q3 25 | 17.6% | 18.9% | ||
| Q2 25 | 12.7% | 47.3% | ||
| Q1 25 | 8.7% | -0.2% | ||
| Q4 24 | 22.6% | 9.6% | ||
| Q3 24 | 27.4% | 5.8% | ||
| Q2 24 | -4.6% | 0.2% |
净利率PBYIVICR
| Q1 26 | — | 18.3% | ||
| Q4 25 | — | 43.4% | ||
| Q3 25 | 16.2% | 25.6% | ||
| Q2 25 | 11.2% | 42.9% | ||
| Q1 25 | 6.5% | 2.7% | ||
| Q4 24 | — | 10.7% | ||
| Q3 24 | 25.2% | 12.4% | ||
| Q2 24 | -9.6% | -1.4% |
每股收益（稀释后）PBYIVICR
| Q1 26 | — | $0.44 | ||
| Q4 25 | $0.26 | $1.01 | ||
| Q3 25 | $0.17 | $0.63 | ||
| Q2 25 | $0.12 | $0.91 | ||
| Q1 25 | $0.06 | $0.06 | ||
| Q4 24 | $0.40 | $0.24 | ||
| Q3 24 | $0.41 | $0.26 | ||
| Q2 24 | $-0.09 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $404.2M |
| 总债务越低越好 | $22.7M | — |
| 股东权益账面价值 | $130.3M | $754.1M |
| 总资产 | $216.3M | $804.9M |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资PBYIVICR
| Q1 26 | — | $404.2M | ||
| Q4 25 | $97.5M | $402.8M | ||
| Q3 25 | $94.4M | $362.4M | ||
| Q2 25 | $96.0M | $338.5M | ||
| Q1 25 | $93.2M | $296.1M | ||
| Q4 24 | $101.0M | $277.3M | ||
| Q3 24 | $96.7M | $267.6M | ||
| Q2 24 | $96.8M | $251.9M |
总债务PBYIVICR
| Q1 26 | — | — | ||
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — |
股东权益PBYIVICR
| Q1 26 | — | $754.1M | ||
| Q4 25 | $130.3M | $711.6M | ||
| Q3 25 | $115.3M | $630.1M | ||
| Q2 25 | $104.7M | $608.6M | ||
| Q1 25 | $97.1M | $580.3M | ||
| Q4 24 | $92.1M | $570.1M | ||
| Q3 24 | $71.1M | $554.6M | ||
| Q2 24 | $48.5M | $537.2M |
总资产PBYIVICR
| Q1 26 | — | $804.9M | ||
| Q4 25 | $216.3M | $785.8M | ||
| Q3 25 | $202.9M | $710.2M | ||
| Q2 25 | $194.9M | $693.5M | ||
| Q1 25 | $196.2M | $665.0M | ||
| Q4 24 | $213.3M | $641.1M | ||
| Q3 24 | $220.7M | $632.8M | ||
| Q2 24 | $205.0M | $613.2M |
负债/权益比PBYIVICR
| Q1 26 | — | — | ||
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | — |
| 自由现金流经营现金流 - 资本支出 | $14.4M | — |
| 自由现金流率自由现金流/营收 | 19.1% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $41.7M | — |
8季度趋势，按日历期对齐
经营现金流PBYIVICR
| Q1 26 | — | — | ||
| Q4 25 | $14.4M | $15.7M | ||
| Q3 25 | $9.7M | $38.5M | ||
| Q2 25 | $14.1M | $65.2M | ||
| Q1 25 | $3.6M | $20.1M | ||
| Q4 24 | $15.6M | $10.1M | ||
| Q3 24 | $11.0M | $22.6M | ||
| Q2 24 | $1.0M | $15.6M |
自由现金流PBYIVICR
| Q1 26 | — | — | ||
| Q4 25 | $14.4M | $10.2M | ||
| Q3 25 | $9.7M | $34.5M | ||
| Q2 25 | $14.1M | $59.0M | ||
| Q1 25 | $3.6M | $15.6M | ||
| Q4 24 | $15.6M | $8.4M | ||
| Q3 24 | $11.0M | $14.1M | ||
| Q2 24 | $1.0M | $9.4M |
自由现金流率PBYIVICR
| Q1 26 | — | — | ||
| Q4 25 | 19.1% | 9.5% | ||
| Q3 25 | 17.7% | 31.2% | ||
| Q2 25 | 26.8% | 61.5% | ||
| Q1 25 | 7.7% | 16.6% | ||
| Q4 24 | 26.4% | 8.7% | ||
| Q3 24 | 13.7% | 15.2% | ||
| Q2 24 | 2.1% | 11.0% |
资本支出强度PBYIVICR
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 5.2% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 6.5% | ||
| Q1 25 | 0.1% | 4.8% | ||
| Q4 24 | 0.0% | 1.8% | ||
| Q3 24 | 0.0% | 9.1% | ||
| Q2 24 | 0.0% | 7.2% |
现金转化率PBYIVICR
| Q1 26 | — | — | ||
| Q4 25 | — | 0.34× | ||
| Q3 25 | 1.10× | 1.36× | ||
| Q2 25 | 2.41× | 1.58× | ||
| Q1 25 | 1.21× | 7.93× | ||
| Q4 24 | — | 0.99× | ||
| Q3 24 | 0.54× | 1.95× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBYI
暂无分部数据
VICR
| Product revenue | $98.0M | 87% |
| Royalty revenue | $15.0M | 13% |
